| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 0 | 118 | 3.323 | 14.958 | 12.898 | 20.870 | 31.783 | 7.706 | 0 |
| Total Income - EUR | - | 0 | 118 | 3.323 | 14.958 | 12.898 | 20.870 | 31.783 | 7.706 | 0 |
| Total Expenses - EUR | - | 140 | 10.396 | 6.098 | 7.162 | 3.005 | 6.261 | 19.322 | 4.671 | 0 |
| Gross Profit/Loss - EUR | - | -140 | -10.278 | -2.775 | 7.796 | 9.893 | 14.609 | 12.461 | 3.035 | 0 |
| Net Profit/Loss - EUR | - | -140 | -10.279 | -2.809 | 7.646 | 9.498 | 14.058 | 11.763 | 2.940 | 0 |
| Employees | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Dacrimed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | 6.362 | 1 | 2.648 | 2.490 | 4.913 | 14.524 | 13.528 | 3.000 | 274 |
| Inventories | - | 6.314 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 45 | 0 | 1.719 | 1.264 | 360 | 9.391 | 4.380 | 0 | 0 |
| Cash | - | 4 | 1 | 929 | 1.226 | 4.554 | 5.133 | 9.148 | 3.000 | 274 |
| Shareholders Funds | - | -96 | -10.373 | -12.991 | -5.094 | 4.501 | 14.099 | 11.812 | 2.980 | 40 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 6.458 | 10.374 | 15.639 | 7.584 | 413 | 425 | 1.716 | 20 | 234 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Dacrimed Srl